SITC's Guide to Managing Immunotherapy Toxicity (eBook, ePUB)

Redaktion: Ernstoff, Marc S.; Hersey, Peter M.; Diab, Adi M.; Robert, Caroline; Puzanov, Igor

• Format: ePub

Produktbeschreibung

The Society for Immunotherapy of Cancer's handbook,SITC's Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers.

With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.

Key Features:

• Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy
• Provides numerous tables that condense and highlight pertinent information for quick reference
• Describes the various clinical presentations and toxic reactions caused by immunotherapy
• Purchase includes access to the eBook for use on most mobile devices or computer

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.

Produktdetails

• Verlag: Springer Publishing Company
• Seitenzahl: 250
• Erscheinungstermin: 15. März 2019
• Englisch
• ISBN-13: 9780826172150
• Artikelnr.: 55903350

Inhaltsangabe

Foreword
Introduction
Part 1: Immune Checkpoint Inhibitors in the Clinic
Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab
1. Daniel Hartman Johnson and Jianjun Gao
Chapter Two: Overview of PD-1 and PD-L1 Inhibitors
2. Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas
Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor
Combinations
3. Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber
Part 2: Specific Immune Checkpoint Inhibitor Toxicities
Chapter Four: General Principles of Immune-Related Toxicities
4. Osama E. Rahma and Patrick A. Ott
Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and
Pruritus
5. Jennifer Wu and Mario E. Lacouture
Chapter Six: Musculoskeletal and Rheumatologic Toxicities
6. Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor
Chapter Seven: Immune-Related Gastrointestinal Toxicities
7. Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang
Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades
8. Vickie R. Shannon
Chapter Nine: Immune-Related Endocrinopathies Associated with Immune
Checkpoint Inhibitors
9. Rajeev Sharma, Ha Nguyen, Ramona Dadu
Chapter Ten: Neurologic Adverse Events and Neurologic Complications
10. Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul
Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint
Inhibitors
11. Pankit Vachhani, Igor Puzanov, Javid J. Moslehi
Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint
Inhibitors
12. Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges
Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins
13. George L. Chen, Caroline Robert, Alexander M. Lesokhin
Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation
14. Liliya Golas and Dimitra Skondra
Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in
Special Patient Populations
15. Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto
Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint
Inhibitor Therapy
16. Eric D. Hansen, Michelle Walter, Amy A. Case
Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer
Therapies
17. Christine Kohn, Natalia Shcherbakova, Alberto J. Montero